Iptacopan for autoimmune hemolytic anemia that hasn't improved
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new oral medication called iptacopan for people with AIHA that hasn't improved with steroids or that keeps coming back. The goal is to see if the drug can help raise your hemoglobin and manage the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with autoimmune hemolytic anemia (AIHA), a condition where your immune system attacks your red blood cells.
- You have tried steroid treatment (like prednisone) and it didn't work well enough, you needed too much, your anemia came back, or you couldn't take it.
- Your hemoglobin (the part of your blood that carries oxygen) is below 100 g/L.
- You are able to get vaccinated against certain bacteria or take antibiotics to prevent infection.
- You have no active infections, cancer history (except certain cured skin or cervical cancers), or major organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called Inaticabtagene Autoleucel (a personalized treatment made from your own immune cells) for people with autoimmune hemolytic anemia that has not improved after three or more prior treatments. The goal is to see if this therapy can stop the immune system from destroying red blood cells and help increase your hemoglobin levels.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This trial tests a new oral medicine called iptacopan for people who have a serious blood vessel complication after a stem cell transplant (TA-TMA) that is not improving with usual treatments. The goal is to see if iptacopan can help stop the damage and improve recovery.
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
This program gives access to the drug iptacopan for patients with serious conditions who have no other options. It is not a standard clinical trial but a special way to get the drug when all approved treatments have failed or are not suitable.
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
Hear when a new AIHA - Warm Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.